- Home
- IPHA vs RDZN Comparison
IPHA vs RDZN Comparison
Compare IPHA & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IPHA | RDZN |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | France | United States |
| Employees | 174 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.4M | 148.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IPHA | RDZN |
|---|---|---|
| Price | $1.62 | $1.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | 24.1K | ★ 83.9K |
| Earning Date | 03-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $180.36 | $33.77 |
| Revenue Next Year | N/A | $51.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $0.68 |
| 52 Week High | $2.63 | $2.56 |
Technical Indicators
Market Signals| Indicator | IPHA | RDZN |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 46.56 |
| Support Level | $1.18 | $1.12 |
| Resistance Level | $1.83 | $1.21 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 46.51 | 50.00 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.